From Bench to Bedside and Back Again: Strategies for Effectively Leveraging Pre-Clinical Data to Accelerate R&D
The drug discovery process is complex and time-consuming, with an average development time of 10+ years and hundreds of millions to billions of dollars spent to receive regulatory approval. As recently as 2015, researchers concluded that anywhere from 50-80% of pre-clinical animal (in vivo) research data was irreproducible,1 representing a monetary loss of more than $28 billion. For an industry renowned for advancing human knowledge—it’s shocking to realize that 90% of in vivo study data is captured and recorded either on paper, disparate legacy software like spreadsheets, or other in-house developed systems.
This lively discussion will feature experts from both sides of the informatics and IT canyon, focusing on the best ways to achieve maximum value and effectiveness of the in vivo research process.
Discussion will include:
- Current in vivo study management practices and processes. How did we get here?
- Best practices for capturing reproducible and accurate in vivo data to reduce failure in clinical trials – the most expensive phase of drug development.
- Opportunities to streamline in vivo study management, reducing costly human errors and maximizing already constrained resources.
- The importance of change management programs and strategic implementation of modern research tools and methods- including best practices for measuring your organization’s current tech stack.
- How implementing standardized, traceable data management in the pre-clinical environment not only encourages collaboration but can enable new insights from both the bench and the bedside.
1 The Economics of Reproducibility in Preclinical Research
Freedman LP, Cockburn IM, Simcoe TS (2015) The Economics of Reproducibility in Preclinical Research. PLOS Biology 13(6): e1002165. https://doi.org/10.1371/journal.pbio.1002165
Speakers
